Compagnie Lombard Odier SCmA’s Aurinia Pharmaceuticals AUPH Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$136K	Hold	8,000	–	–	﹤0.01%	301
2026 Q1	$119K	Hold	8,000	–	–	﹤0.01%	285
2025 Q4	$128K	Hold	8,000	–	–	﹤0.01%	283
2025 Q3	$88.4K	Hold	8,000	–	–	﹤0.01%	314
2025 Q2	$67.8K	Hold	8,000	–	–	﹤0.01%	311
2025 Q1	$64.3K	Hold	8,000	–	–	﹤0.01%	339
2024 Q4	$71.8K	Sell	8,000 -57,000	-88%	-$465K	﹤0.01%	312
2024 Q3	$476K	Hold	65,000	–	–	0.01%	183
2024 Q2	$371K	Buy	65,000 +40,000	+160%	+$211K	0.01%	198
2024 Q1	$125K	Hold	25,000	–	–	﹤0.01%	290
2023 Q4	$225K	Buy	25,000 +2,000	+9%	+$16.5K	﹤0.01%	274
2023 Q3	$179K	Hold	23,000	–	–	﹤0.01%	286
2023 Q2	$223K	Hold	23,000	–	–	0.01%	253
2023 Q1	$252K	Hold	23,000	–	–	0.01%	253
2022 Q4	$100K	Hold	23,000	–	–	﹤0.01%	389
2022 Q3	$173K	Hold	23,000	–	–	0.01%	317
2022 Q2	$231K	Buy	23,000 +3,000	+15%	+$33.5K	0.01%	274
2022 Q1	$248K	Buy	20,000 +9,000	+82%	+$139K	0.01%	282
2021 Q4	$251K	Buy	+11,000	New	+$261K	0.01%	329

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Compagnie Lombard Odier SCmA's AUPH Position: Q2 2026 in Review

Compagnie Lombard Odier SCmA held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 8,000 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #301.

Compagnie Lombard Odier SCmA first reported a position in AUPH in Q4 2021 and has held it in 19 quarters since. The position peaked at $476K in Q3 2024. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Compagnie Lombard Odier SCmA held 8,000 shares of Aurinia Pharmaceuticals worth $136K as of Q2 2026.
Compagnie Lombard Odier SCmA left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
Aurinia Pharmaceuticals made up ﹤0.01% of Compagnie Lombard Odier SCmA's portfolio in Q2 2026, its #301 holding.
Compagnie Lombard Odier SCmA first reported a position in Aurinia Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
Compagnie Lombard Odier SCmA's Aurinia Pharmaceuticals position peaked at $476K in Q3 2024.
282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2026, filed 29 Jul 2026.